Table Graph
      published meta-analysis   sensitivity analysis   studies

tocilizumab in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsRashad, 2021 2.86 [1.36; 6.01] Rashad, 2021 (REV) 2.86 [1.36; 6.01] 2.86[1.69; 4.83]Rashad, 2021, Rashad, 2021 (REV)20%298seriousnot evaluable deathsdetailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 (REV) 2.17 [1.14; 4.14] 2.17[1.38; 3.41]Rashad, 2021, Rashad, 2021 (REV)20%298seriousnot evaluable deaths (time to event analysis only)detailed resultsRashad, 2021 2.16 [1.14; 4.09] Rashad, 2021 (REV) 2.17 [1.14; 4.14] 2.17[1.38; 3.41]Rashad, 2021, Rashad, 2021 (REV)20%298seriousnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-14 05:31 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 395 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons